75375-89-2

Basic information

• Product Name: 4-Amino-tricyclo[3.3.1.13,7]decan-1-ol
• Synonyms: 1-Hydroxy-4-aminoadamantane;4-Amino-tricyclo[3.3.1.13,7]decan-1-ol;4-aminoadamantan-1-ol(SALTDATA: HCl)
• CAS NO: 75375-89-2
• Molecular Formula: C₁₀H₁₇NO
• Molecular Weight: 167.24808
• Mol File: 75375-89-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 258-260 °C(Solv: toluene (108-88-3))
• Boiling Point: 275.6±33.0 °C(Predicted)
• Appearance: /
• Density: 1.205
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 15.14±0.40(Predicted)
• CAS DataBase Reference: 4-Amino-tricyclo[3.3.1.13,7]decan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-tricyclo[3.3.1.13,7]decan-1-ol(75375-89-2)
• EPA Substance Registry System: 4-Amino-tricyclo[3.3.1.13,7]decan-1-ol(75375-89-2)

Safety Data

• Hazardous Substances Data: 75375-89-2(Hazardous Substances Data)

Usage

General Description

4-Amino-tricyclo[3.3.1.13,7]decan-1-ol is a chemical compound with the molecular formula C9H17NO. It is a tertiary amine with a tricyclic structure, containing a cyclopropane ring and a cycloheptane ring. 4-Amino-tricyclo[3.3.1.13,7]decan-1-ol has a hydroxyl group attached to the tricyclic structure, making it an amino alcohol. 4-Amino-tricyclo[3.3.1.13,7]decan-1-ol may have potential applications in organic synthesis, pharmaceuticals, and chemical research due to its unique structure and functional groups. However, further research and testing would be necessary to fully understand its properties and potential uses.

Upstream product

• 353241-69-7 C₁₂H₁₈N₂O₄ 
• 20098-19-5 1-hydroxy-4-aminoadamantane hydrochloride 
• 20098-18-4 5-hydroxy-adamantan-2-one oxime 
• 20098-14-0 chemantane 
• 13074-39-0 N-(2-adamantyl)amine 
• 10523-68-9 adamantan-2-amine hydrochloride 

Downstream Products

• 1265898-45-0 C₂₀H₂₄Cl₂N₂O₄S₂ 

Relevant articles and documents

Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells

A collaborative high throughput screen of 1.35 million compounds against mutant (R132H) isocitrate dehydrogenase IDH1 led to the identification of a novel series of inhibitors. Elucidation of the bound ligand crystal structure showed that the inhibitors exhibited a novel binding mode in a previously identified allosteric site of IDH1 (R132H). This information guided the optimization of the series yielding submicromolar enzyme inhibitors with promising cellular activity. Encouragingly, one compound from this series was found to induce myeloid differentiation in primary human IDH1 R132H AML cells in vitro.

The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors

The design and development of a series of highly selective pyrrolidine carboxamide 11β-HSD1 inhibitors are described. These compounds including PF-877423 demonstrated potent in vitro activity against both human and mouse 11β-HSD1 enzymes. In an in vivo assay, PF-877423 inhibited the conversion of cortisone to cortisol. Structure guided optimization effort yielded potent and stable 11β-HSD1 selective inhibitor 42.

NOVEL COMPOUNDS

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.